Montara Therapeutics Secures $1M Michael J. Fox Foundation Grant to Advance Brain-Selective mTOR Therapy for Parkinson's Disease

Montara Therapeutics (搜索)搜索该词条, a preclinical-stage biopharmaceutical company focused on brain-selective therapies, has been awarded a research grant of approximately $1 million from The Michael J. Fox Foundation for Parkinson's Research查看公司主页 (MJFF) to advance a novel therapeutic strategy targeting the mTOR (搜索)搜索该靶点 pathway in Parkinson's disease (搜索)搜索该疾病. Announced June 2, 2026, the funding marks Montara's second grant from MJFF, following a May 2025 award to develop a brain-selective LRRK2 (搜索)搜索该靶点 inhibitor.

The new program will leverage Montara's proprietary BrainOnly™ platform to activate autophagy — the brain's natural protein-clearing machinery — with the goal of clearing toxic α-synuclein (搜索)搜索该靶点 aggregates that characterize Parkinson's disease (搜索)搜索该疾病 pathology, while mitigating the systemic adverse effects that have historically prevented mTOR (搜索)搜索该靶点 inhibitors from reaching patients with neurological conditions.

The mTOR (搜索)搜索该靶点-Autophagy Axis in Parkinson's Disease (搜索)搜索该疾病

Parkinson's disease (搜索)搜索该疾病 is characterized in part by the progressive accumulation of α-synuclein (搜索)搜索该靶点, a toxic protein that clumps together and damages neurons over time. A promising strategy for removing this protein involves activating autophagy, a natural cellular housekeeping process in which cells break down and recycle damaged components.

The mTOR (搜索)搜索该靶点 protein serves as a critical brake on autophagy: when mTOR is active, autophagy is suppressed; when mTOR is inhibited, the brake is released and the cell's protein-clearing machinery is switched on. Drugs that inhibit mTOR — a class that includes rapamycin查看药品详情 and related compounds — have shown encouraging results in clearing α-synuclein (搜索)搜索该靶点 in laboratory models of Parkinson's disease (搜索)搜索该疾病. However, because mTOR plays essential roles throughout the body, systemic mTOR inhibition causes serious side effects, including immune suppression, impaired wound healing, and metabolic disruption, severely limiting the clinical utility of these drugs as neurological therapies.

The BrainOnly™ Platform Approach

Montara's BrainOnly™ platform is designed to address this challenge by pairing a brain-penetrant therapeutic with a proprietary peripheral blocker that prevents the drug from acting outside the brain. This two-drug combination strategy enables brain-specific pharmacology, allowing therapies to target mechanisms underlying neurological disease while minimizing harmful systemic effects.

The company is already advancing its proprietary peripheral blocker, MT1110 (搜索)搜索该药品, toward the clinic in combination with everolimus查看药品详情, an mTOR (搜索)搜索该靶点 inhibitor, to treat tuberous sclerosis complex (搜索)搜索该疾病 (TSC)-related epilepsy — another disease driven by mTOR pathway hyperactivation. The Parkinson's program builds directly on that foundation, applying the same BrainOnly™ approach to a new indication where mTOR-driven autophagy could clear the toxic protein accumulation at the heart of the disease.

Program Scope and Scientific Rationale

Through the MJFF collaboration, funded under the Foundation's Therapeutics Pipeline Program — which supports preclinical and clinical efforts to accelerate new therapies for Parkinson's disease (搜索)搜索该疾病 — Montara will evaluate several clinically utilized mTOR (搜索)搜索该靶点 inhibitors combined with its proprietary peripheral blocker. The goal is to identify novel two-drug combinations that selectively activate autophagy in the brain.

The program will assess these combinations in cell-based systems and Parkinson's disease (搜索)搜索该疾病 animal models to determine which candidates most effectively reduce α-synuclein (搜索)搜索该靶点 accumulation, treat pathology, and exhibit favorable safety profiles. If successful, the project could yield a therapeutic strategy that safely enhances autophagy in the brain, helping remove toxic protein buildup and potentially slowing or even stopping disease progression.

"Our team has spent years working toward a therapy that doesn't just treat the symptoms of Parkinson's but addresses the underlying biology causing neurons to die," said Nicholas T. Hertz, Ph.D., Founder and CEO of Montara Therapeutics (搜索)搜索该词条. "MJFF's continued support reflects the importance of exploring new approaches to Parkinson's disease (搜索)搜索该疾病 biology. The mTOR (搜索)搜索该靶点 pathway is one of the most powerful levers we have for clearing toxic proteins from the brain, and our platform may finally make it safe enough to use."

Expert Perspectives

"The mTOR (搜索)搜索该靶点 pathway represents an important area of investigation in Parkinson's research," said Jessica Tome Garcia, Lead Scientific Program Manager, Translational Research at The Michael J. Fox Foundation. "While the underlying biology is compelling, challenges related to systemic toxicity have limited progress. This work aims to explore approaches that may help address those barriers and advance our understanding of how targeting mTOR-driven autophagy could impact disease biology."

Martin Kampmann, Ph.D., Professor of Biochemistry and Biophysics at UCSF and a Scientific Co-Founder of Montara Therapeutics (搜索)搜索该词条, added: "Our own genome-wide screens in human neurons identified mTOR (搜索)搜索该靶点 signaling as one of the key pathways controlling the accumulation of toxic protein aggregates — and a target with real therapeutic potential. The challenge has always been that you cannot inhibit mTOR systemically without serious consequences for the rest of the body. Montara's BrainOnly™ platform is the most compelling approach I've seen for solving that problem, and this program gives us a direct path to test whether brain-selective mTOR inhibition can reduce pathological protein buildup in Parkinson's disease (搜索)搜索该疾病."

Montara Therapeutics (搜索)搜索该词条 is supported by an investor group that includes founding investor SV Health Investors' Dementia Discovery Fund, Two Bear Capital, KdT Ventures, Dolby Family Ventures, and BEVC.